HC Wainwright reissued their buy rating on shares of Ultragenyx Pharmaceutical ( NASDAQ:RARE – Free Report ) in a report issued on Tuesday morning, Benzinga reports. They currently have a $82.00 target price on the biopharmaceutical company's stock. Several other research firms also recently commented on RARE. Evercore ISI upgraded shares of Ultragenyx Pharmaceutical from an in-line rating to an outperform rating and boosted their price target for the stock from $60.00 to $80.00 in a research note on Tuesday, June 6th.

https://www.dailypolitical.com/2023/08/05/ultragenyx-pharmaceutical-nasdaqrare-receives-buy-rating-from-hc-wainwright.html

#dailypolitical